Industrial Synthesis Route For 3-(4-Chlorobutyryl)-1H-Indol-5-Carbonitrile
- High Yield Acylation: Optimized Friedel-Crafts reactions achieving over 88% conversion rates under controlled temperatures.
- Pharmaceutical Grade: Final product HPLC purity exceeds 99.5% suitable for API intermediate synthesis.
- Bulk Availability: Scalable manufacturing process ensuring consistent supply for global pharmaceutical partners.
The production of 3-(4-chlorobutyryl)-1H-indol-5-carbonitrile (CAS: 276863-95-7) represents a critical step in the value chain for modern antidepressant pharmaceuticals, specifically as a key precursor for Vilazodone. As demand for high-quality intermediates grows, the focus shifts toward robust synthesis route methodologies that balance yield, safety, and industrial purity. This technical overview details the chemical engineering principles required for large-scale production, emphasizing solvent selection, catalyst efficiency, and downstream processing.
Step-by-Step Industrial Synthesis of 3-(4-Chlorobutyryl)-1H-indol-5-carbonitrile
The core chemical transformation involves a Friedel-Crafts acylation between 5-cyanoindole and 4-chlorobutyryl chloride. This reaction requires precise thermal management to prevent polymerization or side reactions at the indole nitrogen. In an industrial setting, the manufacturing process typically begins with the dissolution of 5-cyanoindole in an anhydrous solvent system. Dichloromethane (DCM) is frequently employed due to its solubility profile, though nitromethane blends are also utilized to enhance reaction kinetics.
Upon establishing a nitrogen-inert atmosphere, a Lewis acid catalyst is introduced. Zinc chloride (ZnCl2) and aluminum chloride (AlCl3) are the primary candidates. Data indicates that using zinc chloride at temperatures between -10°C and 5°C can achieve yields upwards of 88%. The acylating agent, 4-chlorobutyryl chloride, is added dropwise to maintain exothermic control. Following the addition, the reaction mixture is stirred at 0°C to 5°C for approximately two hours to ensure complete conversion. Quenching is performed carefully using ice water, followed by neutralization with sodium hydroxide to adjust the pH to 7. The organic phase is then separated, washed with saturated brine, and concentrated.
Solvent and Catalyst Selection for Optimal Yield
Selecting the appropriate solvent and catalyst system is paramount for maximizing industrial purity and minimizing impurities such as N-acylated byproducts. While laboratory scales may tolerate varied conditions, bulk production demands consistency. The use of anhydrous conditions is non-negotiable to prevent hydrolysis of the acid chloride. Furthermore, the choice of recrystallization solvent significantly impacts the final assay. Isopropyl acetate has proven effective for recrystallizing the crude residue, yielding a solid product with HPLC purity greater than 99.5%.
Temperature control during the catalyst addition phase is critical. Exothermic spikes can lead to degradation of the cyano group or chlorobutyl chain. Therefore, industrial reactors are equipped with advanced cooling jackets to maintain the internal temperature within the -10°C to 5°C window. This precision ensures that the synthesis route remains reproducible across different batch sizes, from pilot runs to multi-ton production.
GMP-Compliant Manufacturing Considerations for API Intermediates
Producing intermediates for active pharmaceutical ingredients (APIs) requires adherence to strict quality control protocols. Every batch must be accompanied by a comprehensive Certificate of Analysis (COA). Key parameters include identification via IR and NMR spectroscopy, assay determination by HPLC, and residual solvent analysis. Impurity profiling is essential, particularly for related substances that might carry through to the final drug product.
When sourcing high-purity 3-(4-Chlorobutanoyl)-1H-indole-5-carbonitrile, buyers should verify that the supplier operates under GMP-like standards for intermediates. This includes validated cleaning procedures, documented chain of custody for raw materials, and stability testing. The physical form of the product, typically an off-white to light yellow crystalline powder, must remain stable under recommended storage conditions to prevent degradation of the chlorobutyryl moiety.
Commercial Viability and Bulk Procurement
The economic feasibility of producing this intermediate depends heavily on raw material costs and process efficiency. Optimizing the molar ratio of 5-cyanoindole to 4-chlorobutyryl chloride (typically 1:1.1) helps minimize waste while driving the reaction to completion. Solvent recovery systems are also integrated into the production line to reduce environmental impact and lower the overall bulk price per kilogram.
As a global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. specializes in scaling these complex organic syntheses while maintaining rigorous quality standards. Our facilities are equipped to handle hazardous reagents safely and ensure timely delivery for international supply chains. We understand that consistency is key for pharmaceutical clients who require reliable input materials for their own regulatory filings.
Supply chain resilience is another critical factor. Fluctuations in the availability of specialized indole derivatives can impact production schedules. NINGBO INNO PHARMCHEM CO.,LTD. maintains strategic stock levels of key starting materials to mitigate these risks, ensuring that clients receive their orders without delay. This reliability, combined with competitive pricing structures for tonnage quantities, makes us a preferred partner for long-term contracts.
Technical Specifications Summary
The following table outlines the typical technical parameters expected for industrial-grade 3-(4-Chlorobutyryl)-1H-indol-5-carbonitrile. These specifications serve as a benchmark for quality assurance during procurement.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 276863-95-7 | - |
| Molecular Formula | C13H11ClN2O | - |
| Molecular Weight | 246.69 g/mol | - |
| Appearance | Off-white to Light Yellow Powder | Visual |
| Purity (HPLC) | ≥ 99.5% | Area Normalization |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Residual Solvents | Compliant with ICH Q3C | GC |
In conclusion, the industrial production of 3-(4-chlorobutyryl)-1H-indol-5-carbonitrile requires a sophisticated understanding of organic synthesis and process engineering. By leveraging optimized Friedel-Crafts conditions and strict quality control measures, manufacturers can deliver high-purity intermediates essential for the synthesis of next-generation antidepressants. Partnering with an experienced supplier ensures access to technical expertise and reliable supply chains necessary for successful drug development.